A case of fibromyalgia involving pain throughout the body treated with site-specific targeted pain control by unknown
Nakajima et al. SpringerPlus  (2016) 5:1027 
DOI 10.1186/s40064-016-2572-z
CASE STUDY
A case of fibromyalgia involving pain 
throughout the body treated with site-specific 
targeted pain control
Fukami Nakajima1,2,6*, Satoko Aratani2,3, Hidetoshi Fujita4, Kou Nakatani5, Koshi Makita6 
and Toshishiro Nakajima1,2,4,5
Abstract 
Introduction: Fibromyalgia is characterized by chronic pain and tenderness throughout the body. Patients with 
fibromyalgia are treated with pharmacotherapy and many other therapies. However, because the cause of fibromyal-
gia is unclear, there is currently no clinically effective treatment method.
Case presentation:  We report the case of a patient who developed fibromyalgia after left femoral neck fracture. 
After several caudal epidural blocks for lumbar pain, the pain throughout the body and abnormal discomfort in 
the laryngopharyngeal region reduced. Site-specific targeted pain control was effective in treating his pain and 
discomfort.
Conclusion: The present case suggests that treatment targeting symptoms in one part of the body might produce a 
systemic therapeutic effect in patients with fibromyalgia.
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Introduction
Fibromyalgia is a disease associated with chronic pain 
and tenderness throughout the body; however, its etiol-
ogy is unknown, and it is often accompanied by depres-
sion, fatigue, and sleep disorders (Wolfe 1988, 1990; 
Wolfe et al. 1995). Drug therapy (Imani and Rahimzadeh 
2012; Alimian et al. 2012a, b; Hill et al. 2012; Ablin and 
Buskila 2013), cognitive behavioral therapy (Ablin et  al. 
2013), exercise therapy, nerve block therapy (Bengtsson 
and Bengtsson 1988), alternative therapies (Nakajima 
et al. 2015), and other approaches have been used for the 
treatment of this disease. However, because the cause of 
fibromyalgia is unclear, there is currently no clinically 
effective treatment. The complaints of patients are often 
indistinct, and in some instances, treatment is agonizing. 
It is often difficult to treat pain present over the entire 
body. Herein, we report the effective use of site-specific 
targeted pain control for treating a range of symptoms 
throughout the body in a patient who developed fibromy-
algia after left femoral neck fracture.
Case presentation
Case
The patient was a 42-year-old man (height, 168  cm; 
weight, 68 kg).
History of the present illness
At the age of 37 years, the patient collided with a utility 
pole while riding a bicycle and experienced left femo-
ral neck fracture. He underwent an open reduction and 
internal fixation procedure under general anesthesia, 
and both the surgery and postoperative course were 
uneventful. However, he experienced back pain immedi-
ately after the surgery. He later gradually began to expe-
rience increasingly severe pain in all body muscles, pain 
in his joints, and discomfort in the laryngopharyngeal 
area. Despite multiple hospital visits, the cause of his 
pain remained unknown, and in April 2013, at the age 
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of 39 years, he was diagnosed with fibromyalgia accord-
ing to the diagnostic criteria of the American College 
of Rheumatology (Wolfe et  al. 1990) at the outpatient 
fibromyalgia department of our hospital, which special-
izes in fibromyalgia treatment. It is sometimes difficult 
to discriminate fibromyalgia from psychiatry illnesses; 
however, he was not diagnosed with any psychiatric dis-
orders by the psychiatrist at our hospital. After diagnosis, 
he received medication (pregabalin 125  mg/day per os, 
rebamipide 300  mg/day per os, milnacipran hydrochlo-
ride 7.5 mg/day per os, and etizolam 0.5 mg/day per os) 
and underwent rehabilitation. For improved sympto-
matic relief, he visited the outpatient pain department 
of our hospital in September 2014, followed by com-
bined treatments at the outpatient fibromyalgia and pain 
departments of our hospital.
Examination findings at the first visit
At the first visit to the outpatient pain department, the 
patient had a Widespread Pain Index and Symptom 
Severity (WPISS) score (Fitzcharles et  al. 2012) of 23 
points (WPI, 15 points; SS, 8 points), and a score of 750 
in assessments with PainVision (Nipro Co., Osaka, Japan) 
(Kato 2011), a quantitative pain analysis device.
Course of treatment
At the first visit to the outpatient pain department, the 
patient complained of severe pain throughout the body. 
His answer to the question “Where does it hurt most?” 
was “The worst discomforts are the abnormal sensation 
in my laryngopharyngeal area and the back pain.” He 
experienced very severe back pain in the region from 
Th3 to Th7. Therefore, he was administered trigger point 
injections (1 mL of 0.5 % lidocaine at each tender point) 
at the painful areas on his back. At each visit, approxi-
mately ten tender locations were treated. He was admin-
istered one set of trigger point injections monthly for 
4  months, and each time, the pain subsided for several 
days after treatment but returned unabated after sev-
eral days. Five months after his first visit to the outpa-
tient pain department, we explained the methodologies, 
actions, effects, and complications of stellate ganglion 
block, thoracolumbar epidural block, and caudal epidural 
block. He selected caudal epidural block, as it has a low 
risk of complications such as subarachnoid puncture. He 
underwent caudal epidural block (3  mL of 0.2  % ropiv-
acaine  +  6  mL of saline  +  1.65  mg of dexamethasone) 
for his lumbar pain during an outpatient visit. Immedi-
ately following the caudal epidural block, not only his 
lumbar pain, but also his upper back pain was alleviated 
for approximately 2  weeks. Therefore, he underwent 
another caudal epidural block at his own request in the 
sixth month during an outpatient visit. His back pain 
and the abnormal sensation in the laryngopharyngeal 
area were alleviated for approximately 3 weeks after the 
second block. He continued receiving caudal epidural 
blocks once a month, and after a total of four blocks, 
his back pain was alleviated for approximately 3  weeks 
after the block, and the abnormal sensation in the lar-
yngopharyngeal area almost disappeared. After approxi-
mately 3 weeks, the pain returned; however, the intensity 
was much lower than that at the first visit. On assessing 
his pain using PainVision (Kato 2011), we found that his 
PainVision score of 750 at the first visit reduced to 139 
at the ninth month (1  month after the fourth epidural 
block). Medication was used as an adjunct therapy at the 
outpatient fibromyalgia clinic. The patient’s mental con-
dition might have contributed to his symptoms associ-
ated with fibromyalgia; however, there was no change in 
his prescription drug regimen and his mental condition 
during the period presented in this report.
Discussion
The degree of pain and abnormal discomfort in our 
patient remained unchanged for 1  year before his first 
visit to our pain clinic; moreover, the medication pre-
scription had been the same for the past 6 months. Fur-
thermore, his mental state did not change around the 
time of nerve block administration. Nevertheless, his 
pain was significantly alleviated immediately after the 
nerve block. Based on these findings, we believe that 
the degree of pain and abnormal discomfort mainly 
decreased as result of the caudal epidural blocks. We 
hypothesized that for fibromyalgia patients when pain 
in one part of the body changes (such as at fibromyalgia 
onset), it can affect other parts of the body that are not 
anatomically related to the area of innervation.
The proposed mechanisms for fibromyalgia include 
failure of the descending pain modulatory system (La 
Cesa et al. 2014; Macian et al. 2015) and central sensitiza-
tion (Fleming and Volcheck 2015; Staud et al. 2001); how-
ever, its causes are not clear.
According to the Practice Guideline for Fibromyal-
gia 2013 (edited by the Japan College of Fibromyalgia 
Investigation), the initial pain in fibromyalgia triggers 
subsequent pain, and the pain gradually spreads, in no 
particular order, to areas with no anatomical connection 
to the area of innervation (Japan College of Fibromyalgia 
Investigation 2013). As such, fibromyalgia often involves 
pain in only a part of the body at onset, which then grad-
ually spreads to other parts until pain is felt throughout 
the body.
In the present case, it was inferred from the interview 
of the patient that the femoral neck fracture triggered 
fibromyalgia and that the pain in the femoral region grad-
ually spread throughout the body. It is possible that even 
Page 3 of 3Nakajima et al. SpringerPlus  (2016) 5:1027 
after treatment of his femoral neck fracture, cellular fir-
ing of posterior horn neurons at the level corresponding 
to the fracture continued, resulting in central sensitiza-
tion. However, as the onset mechanism of fibromyalgia 
is unclear, it is unknown how the femoral pain affected 
other parts of the body. Additionally, when pain is alle-
viated, it is possible that pain changes in one part of the 
body could affect pain in other parts through the same 
mechanism involved in fibromyalgia onset.
Incorrect information transmission at the central level, 
such as the thalamus, might be involved in the mecha-
nism of onset of fibromyalgia, and we believe that pain 
changes in one part of the body might affect pain in other 
parts of the body both at the time of fibromyalgia onset 
and after onset. It is not clear whether this hypothesis 
is accurate. Therefore, additional studies are required to 
understand the mechanism.
Conclusions
This case report suggests that a treatment targeting 
symptoms in one part of the body and the alleviation of 
the part of the body might produce a therapeutic effect 
throughout the body in patients with fibromyalgia. Clini-
cians should not give up on treatment goals, even when 
there are many target regions presenting symptoms 
requiring treatment.
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